<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>7658</number>
    <updateDate>2022-12-29T23:48:32Z</updateDate>
    <updateDateIncludingText>2022-12-29T23:48:32Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2022-05-03</introducedDate>
    <congress>117</congress>
    <constitutionalAuthorityStatementText>
      <![CDATA[<pre>[Congressional Record Volume 168, Number 73 (Tuesday, May 3, 2022)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. O'HALLERAN:H.R. 7658.Congress has the power to enact this legislation pursuantto the following:Clause 18, section 8 of article 1 of the Constitution[Page H4714]</pre>]]>
    </constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2022-05-03T14:02:45Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Food and Drug Amendments of 2022</title>
        <congress>117</congress>
        <number>7667</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-06-09</actionDate>
          <text>Received in the Senate.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <congress>117</congress>
        <number>4152</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-05</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDASLA Act of 2022</title>
        <congress>117</congress>
        <number>4348</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-07-13</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2022-05-03</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-05-03</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2022-05-03</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>O000171</bioguideId>
        <fullName>Rep. O'Halleran, Tom [D-AZ-1]</fullName>
        <firstName>Tom</firstName>
        <lastName>O'Halleran</lastName>
        <party>D</party>
        <state>AZ</state>
        <identifiers>
          <bioguideId>O000171</bioguideId>
        </identifiers>
        <district>1</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>L000589</bioguideId>
        <fullName>Rep. Lesko, Debbie [R-AZ-8]</fullName>
        <firstName>Debbie</firstName>
        <lastName>Lesko</lastName>
        <party>R</party>
        <state>AZ</state>
        <identifiers>
          <bioguideId>L000589</bioguideId>
        </identifiers>
        <district>8</district>
        <sponsorshipDate>2022-05-03</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects/>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2022-05-03</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2022-09-20T17:34:17Z</updateDate>
        <text>
          <![CDATA[ <p>This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.</p>]]>
        </text>
      </summary>
    </summaries>
    <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2022-05-03T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117hr7658ih/xml/BILLS-117hr7658ih.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date/>
        <formats/>
        <type/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2022-05-03</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
